Epic Sciences, Inc. and its research partners today report the use of the company’s new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of...
Read More »Epic Sciences, Inc. and its research partners today report the use of the company’s new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of...
Read More »